Biotechs Eye Macular Degeneration
This article was originally published in Start Up
Executive Summary
Spurred by the commercial success of Lucentis, start-ups developing new therapeutics for AMD tap into a growing understanding of the pathogenesis of the disease. In this issue, we profile five emerging AMD drug developers: Acucela, Iconic Therapeutics, MacuCLEAR, Ophthotech, Optherion and Sirion Therapeutics.
You may also be interested in...
Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form
“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.
Imagen's Ophthalmology In-Licensing Strategy Attracts $40M Series A
With a plan to take advantage of scientific advances suggesting that compounds for cancer and other diseases may have facility in the eye, Imagen will seek ideal candidates for dry AMD.
Imagen's Ophthalmology In-Licensing Strategy Attracts $40M Series A
With a plan to take advantage of scientific advances suggesting that compounds for cancer and other diseases may have facility in the eye, Imagen will seek ideal candidates for dry AMD.